An Embarrassment of Riches: Treatment Sequencing in Gastrointestinal Cancers

Are there ways to think about de-escalation to maintenance therapy, again, to prolong the quality of life for a patient while not sacrificing overall survival? Q/ What are the barriers to addressing the issue of treatment sequencing? [...]if they have a driver gene alteration, that is going to affec...

Full description

Saved in:
Bibliographic Details
Published inOncology (Williston Park, N.Y.) Vol. 38; no. 7; p. 287
Main Author Goff, Laura W
Format Journal Article
LanguageEnglish
Published Monmouth Junction Intellisphere, LLC 01.07.2024
MultiMedia Healthcare Inc
Subjects
Algorithms
Antimitotic agents
Antineoplastic agents
Cancer
Cancer therapies
Care and treatment
Chemotherapy
Cholangiocarcinoma
Clinical trials
Colorectal cancer
Disease
Drug therapy
Immunotherapy
Kinases
Liver cancer
Liver cirrhosis
Monoclonal antibodies
Patients
Toxicity
Online AccessGet full text

Cover

More Information
Summary:Are there ways to think about de-escalation to maintenance therapy, again, to prolong the quality of life for a patient while not sacrificing overall survival? Q/ What are the barriers to addressing the issue of treatment sequencing? [...]if they have a driver gene alteration, that is going to affect our choices.5 We also need to evaluate other potential overlapping toxicities. [...]if patients have preexisting neuropathy, oxaliplatin may not be a particularly good choice.2 As additional lines of therapy are being considered, the likelihood of benefit gets smaller, which makes an in-depth discussion on the patient's goals and wishes critically important. Or is it better to maximize our immunotherapy up front, and get a high response rate?
ISSN:0890-9091